Concepedia

Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort

Katrina Morris, John F. Golding, Claire Blesing, D. Gareth Evans, Rosalie E. Ferner, K. Foweraker, Dorothy Halliday, Catherine McBain, Martin G. McCabe, Angela Swampillai,

Journal of Neuro-Oncology · 2016 · 52 citations · 14 references

DOI

Concepts

References

14

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Scott R. Plotkin, Anat Stemmer‐Rachamimov, Fred G. Barker et al. · New England Journal of Medicine · 2009 · 529 citations · Full text

, , +16

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Scott R. Plotkin, Vanessa L. Merker, Chris Halpin et al. · Otology & Neurotology · 2012 · 253 citations · Full text

, , +15

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

V.-F. Mautner, Rosa Nguyen, H. Kutta et al. · Neuro-Oncology · 2009 · 146 citations · Full text

, , +12

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

Jaishri O. Blakeley, Xiaobu Ye, Dan G. Duda et al. · Journal of Clinical Oncology · 2016 · 139 citations · Full text

, , +16

Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients

Fabio P. Nunes, Vanessa L. Merker, Dominique Jennings et al. · PLoS ONE · 2013 · 116 citations · Full text

, , +17